The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 10, 2017
Filed:
Nov. 17, 2015
Applicant:
Genentech, Inc., South San Francisco, CA (US);
Inventors:
James John Crawford, San Francisco, CA (US);
Daniel Fred Ortwine, San Ramon, CA (US);
BinQing Wei, Belmont, CA (US);
Wendy B. Young, San Mateo, CA (US);
Assignee:
Genentech, Inc., South San Francisco, CA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/00 (2006.01); A61K 31/4985 (2006.01); C07D 487/14 (2006.01); C07D 471/04 (2006.01); C07D 471/14 (2006.01); C07D 487/04 (2006.01); C07D 495/04 (2006.01); C07D 519/00 (2006.01); A61K 31/496 (2006.01); A61K 31/5025 (2006.01); A61K 31/506 (2006.01); A61K 31/53 (2006.01); A61K 31/5377 (2006.01); A61K 31/5383 (2006.01); A61K 45/06 (2006.01); C07D 495/14 (2006.01); C07D 498/04 (2006.01); A61K 31/4995 (2006.01); A61K 31/501 (2006.01); C07D 487/08 (2006.01); C07D 513/04 (2006.01); A61K 31/495 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4985 (2013.01); A61K 31/495 (2013.01); A61K 31/496 (2013.01); A61K 31/4995 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/5025 (2013.01); A61K 31/53 (2013.01); A61K 31/5377 (2013.01); A61K 31/5383 (2013.01); A61K 45/06 (2013.01); C07D 471/04 (2013.01); C07D 471/14 (2013.01); C07D 487/04 (2013.01); C07D 487/08 (2013.01); C07D 487/14 (2013.01); C07D 495/04 (2013.01); C07D 495/14 (2013.01); C07D 498/04 (2013.01); C07D 513/04 (2013.01); C07D 519/00 (2013.01);
Abstract
Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.